Analysts Anticipate Conatus Pharmaceuticals Inc. (CNAT) Will Announce Earnings of $0.02 Per Share
Wall Street brokerages predict that Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) will announce earnings of $0.02 per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Conatus Pharmaceuticals’ earnings, with estimates ranging from ($0.06) to $0.09. Conatus Pharmaceuticals reported earnings per share of ($0.31) during the same quarter last year, which would suggest a positive year over year growth rate of 106.5%. The company is expected to announce its next earnings report on Tuesday, November 14th.
Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Conatus Pharmaceuticals.
Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.02). The business had revenue of $10.00 million during the quarter, compared to analyst estimates of $9.33 million. During the same period in the prior year, the firm posted ($0.30) EPS.
Several equities research analysts have weighed in on CNAT shares. Zacks Investment Research upgraded Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Stifel Nicolaus reiterated a “buy” rating and issued a $10.00 price objective on shares of Conatus Pharmaceuticals in a report on Thursday, August 3rd. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Conatus Pharmaceuticals in a research report on Thursday, June 29th. Finally, Seaport Global Securities began coverage on Conatus Pharmaceuticals in a research report on Friday. They issued a “buy” rating and a $16.00 target price for the company. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Conatus Pharmaceuticals has a consensus rating of “Buy” and an average price target of $16.17.
Shares of Conatus Pharmaceuticals (NASDAQ:CNAT) traded down 1.54% during midday trading on Monday, reaching $5.74. The company’s stock had a trading volume of 525,552 shares. The company’s market capitalization is $172.22 million. Conatus Pharmaceuticals has a 12-month low of $1.45 and a 12-month high of $9.40. The company’s 50-day moving average price is $5.54 and its 200 day moving average price is $5.82.
Several large investors have recently made changes to their positions in the company. Acadian Asset Management LLC raised its position in shares of Conatus Pharmaceuticals by 641.1% in the 2nd quarter. Acadian Asset Management LLC now owns 1,097,945 shares of the biotechnology company’s stock worth $6,324,000 after acquiring an additional 949,785 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Conatus Pharmaceuticals by 31.2% in the 2nd quarter. Vanguard Group Inc. now owns 1,006,890 shares of the biotechnology company’s stock worth $5,800,000 after acquiring an additional 239,373 shares in the last quarter. State Street Corp bought a new position in shares of Conatus Pharmaceuticals in the 2nd quarter worth approximately $2,092,000. Northern Trust Corp raised its position in shares of Conatus Pharmaceuticals by 640.6% in the 2nd quarter. Northern Trust Corp now owns 297,152 shares of the biotechnology company’s stock worth $1,712,000 after acquiring an additional 257,030 shares in the last quarter. Finally, Numeric Investors LLC bought a new position in shares of Conatus Pharmaceuticals in the 2nd quarter worth approximately $1,620,000. 33.13% of the stock is owned by hedge funds and other institutional investors.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.